Swayze Eric 4

Accession 0000874015-26-000072

CIK 0000874015other

View on SEC.gov Company Profile

Filed

Jan 19, 7:00 PM ET

Accepted

Jan 20, 8:21 PM ET

Size

22.3 KB

Accession

0000874015-26-000072

Insider Transaction Report

Form 4

Period: 2026-01-15

IONIS PHARMACEUTICALS INCIONS

Swayze Eric

EVP Research

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-15+21,366→ 51,819 total
Sale
Common Stock
[F2][F3]
2026-01-16$75.34/sh−9,884$744,661→ 41,935 total
Exercise/Conversion
Common Stock
[F1]
2026-01-15+111→ 367 total(indirect: by Son)
Sale
Common Stock
[F2]
2026-01-16$75.97/sh−49$3,723→ 318 total(indirect: by Son)
Award
Performance Restricted Stock Units
[F4][F5]
2026-01-15+25,800→ 90,282 total
Exercise: $0.00From: 2029-01-15→ Common Stock (25,800 underlying)
Exercise/Conversion
Restricted Stock Unit
[F6][F7]
2026-01-15−21,366→ 39,251 total
Exercise: $0.00From: 2026-01-15→ Common Stock (21,366 underlying)
Award
Restricted Stock Unit
[F8][F6][F7]
2026-01-15+9,675→ 48,926 total
Exercise: $0.00From: 2027-01-15→ Common Stock (9,675 underlying)
Exercise/Conversion
Restricted Stock Unit
[F6][F7]
2026-01-15−111→ 386 total(indirect: by Son)
Exercise: $0.00From: 2026-01-15→ Common Stock (111 underlying)
Award
Restricted Stock Unit
[F9][F6][F7]
2026-01-15+225→ 611 total(indirect: by Son)
Exercise: $0.00From: 2027-01-15→ Common Stock (225 underlying)

Footnotes (9)

[F1]Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
[F2]The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.26 to $75.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
[F5]The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
[F6]Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
[F7]Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
[F8]Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
[F9]Grant to reporting person's son of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

Signature

By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze|2026-01-20

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

IONIS PHARMACEUTICALS INC

CIK 0000874015

→

Entity typeother

Related Parties

filerCIK 0001791058

Filing Metadata

Form type: 4
Filed: Jan 19, 7:00 PM ET
Accepted: Jan 20, 8:21 PM ET
Size: 22.3 KB

View on SEC.gov